company background image
600645 logo

Vcanbio Cell & Gene Engineering SHSE:600645 Stock Report

Last Price

CN¥16.49

Market Cap

CN¥7.6b

7D

2.5%

1Y

-3.8%

Updated

22 Jul, 2024

Data

Company Financials

Vcanbio Cell & Gene Engineering Corp., Ltd

SHSE:600645 Stock Report

Market Cap: CN¥7.6b

600645 Stock Overview

Primarily engages in the preparation and storage of cell detection tests in the People’s Republic of China.

600645 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance2/6
Financial Health6/6
Dividends0/6

Rewards

Risk Analysis

No risks detected for 600645 from our risk checks.

Vcanbio Cell & Gene Engineering Corp., Ltd Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Vcanbio Cell & Gene Engineering
Historical stock prices
Current Share PriceCN¥16.49
52 Week HighCN¥21.99
52 Week LowCN¥12.88
Beta0.25
11 Month Change-0.42%
3 Month Change3.65%
1 Year Change-3.85%
33 Year Change-14.56%
5 Year Change-6.94%
Change since IPO532.59%

Recent News & Updates

Does Vcanbio Cell & Gene Engineering (SHSE:600645) Have A Healthy Balance Sheet?

May 24
Does Vcanbio Cell & Gene Engineering (SHSE:600645) Have A Healthy Balance Sheet?

Vcanbio Cell & Gene Engineering's (SHSE:600645) Soft Earnings Are Actually Better Than They Appear

May 02
Vcanbio Cell & Gene Engineering's (SHSE:600645) Soft Earnings Are Actually Better Than They Appear

Recent updates

Does Vcanbio Cell & Gene Engineering (SHSE:600645) Have A Healthy Balance Sheet?

May 24
Does Vcanbio Cell & Gene Engineering (SHSE:600645) Have A Healthy Balance Sheet?

Vcanbio Cell & Gene Engineering's (SHSE:600645) Soft Earnings Are Actually Better Than They Appear

May 02
Vcanbio Cell & Gene Engineering's (SHSE:600645) Soft Earnings Are Actually Better Than They Appear

Subdued Growth No Barrier To Vcanbio Cell & Gene Engineering Corp., Ltd's (SHSE:600645) Price

Apr 24
Subdued Growth No Barrier To Vcanbio Cell & Gene Engineering Corp., Ltd's (SHSE:600645) Price

Shareholder Returns

600645CN BiotechsCN Market
7D2.5%2.3%0.2%
1Y-3.8%-21.1%-16.6%

Return vs Industry: 600645 exceeded the CN Biotechs industry which returned -21.1% over the past year.

Return vs Market: 600645 exceeded the CN Market which returned -16.6% over the past year.

Price Volatility

Is 600645's price volatile compared to industry and market?
600645 volatility
600645 Average Weekly Movement6.4%
Biotechs Industry Average Movement6.1%
Market Average Movement5.9%
10% most volatile stocks in CN Market9.1%
10% least volatile stocks in CN Market3.9%

Stable Share Price: 600645's share price has been volatile over the past 3 months.

Volatility Over Time: 600645's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19922,209Hongqi Wangwww.vcanbio.com

Vcanbio Cell & Gene Engineering Corp., Ltd, together with its subsidiaries, primarily engages in the preparation and storage of cell detection tests in the People’s Republic of China. The company provides cell test preparation and storage services for umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental sub totipotent stem cells, immune cells, adipose stem cells, and dental stem cells. It also provides genetic testing services related to non-invasive prenatal genetic testing during pregnancy, genetic testing for drug safety guidance, disease genetic testing, and disease susceptibility testing for children and adults; and in vitro diagnostic raw materials, such as monoclonal antibodies and polyclonal antibody products.

Vcanbio Cell & Gene Engineering Corp., Ltd Fundamentals Summary

How do Vcanbio Cell & Gene Engineering's earnings and revenue compare to its market cap?
600645 fundamental statistics
Market capCN¥7.60b
Earnings (TTM)CN¥109.23m
Revenue (TTM)CN¥1.61b

69.7x

P/E Ratio

4.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
600645 income statement (TTM)
RevenueCN¥1.61b
Cost of RevenueCN¥509.68m
Gross ProfitCN¥1.10b
Other ExpensesCN¥991.05m
EarningsCN¥109.23m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Aug 30, 2024

Earnings per share (EPS)0.24
Gross Margin68.34%
Net Profit Margin6.78%
Debt/Equity Ratio0.9%

How did 600645 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.